Dr Mark Porter: “Part of the challenge is that IBS is unlikely to be one disorder”At least six million people in the UK are regularly troubled by symptoms of irritable bowel syndrome (IBS), so it should come as no surprise that an effective treatment has long been the holy grail of pharmaceutical companies working in the gastrointestinal arena. They are yet to make a significant breakthrough. The latest advance, however, comes from the US, where researchers at the prestigious Mayo Clinic have announced that pregabalin — a drug used to treat neuralgia and anxiety — eases the discomfort associated with IBS. Yet it is early days and pregabalin may go the way of other breakthroughs in this…

Source: The Times October 17, 2016 16:03 UTC